Saw, Hole WESTWARD Bi-Metal, 29VU19 in., 2 Other Metalworking Drills

  1. Home
  2. Saw, Hole WESTWARD Bi-Metal, 29VU19 in., 2
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
WESTWARD Hole Saw, Bi-Metal, 2 in., 29VU19
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Application: Wood, Plastic, Nail-Embedded Wood, Plywood, Pipe, Stainless Steel
Saw Dia.: 2" Arbor Design: Not Included
Shank Size: 3/8" Hex, 7/16" Hex Hole Saw Product Grouping: Hole Saws
Teeth per Inch: 4/6 Impact Rated: No
Thread Size: 5/8"-18 Item: Hole Saw
Tooth Material Grade: M3 Max. Cutting Depth: 1-1/2"
Tooth Material: Bi-Metal Pilot Drill Size: 1/4" x 4" L, 1/4" x 3" L
Package Quantity: 1 Primary Saw Application: Wood


Replacement Arbor No.: No. 29VU98 or 29VX02


Replacement Pilot Drill No.: Mfr. No. 29VX08, 29VU93


published on tue nov 09 2021

Saw, Hole WESTWARD Bi-Metal, 29VU19 in., 2 Other Metalworking Drills

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Saw, Hole WESTWARD Bi-Metal, 29VU19 in., 2 Other Metalworking Drills

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.